newsfilter
← Latest News
Business Wire·

Rallybio Reports Second Quarter 2024 Financial Results and Provides Business Updates

– On Track to Initiate RLYB212 Phase 2 Dose Confirmation Trial in Pregnant Women at Higher Risk of FNAIT in 4Q 2024 – – $88.6 Million in Cash, Cash Equivalents, and Marketable Securities as of June 30, 2024 Provides